Thermo Fisher Scientific
Thermo Fisher Scientific is a globally renowned leader in the scientific solutions and healthcare sectors, with a major footprint in the proteomics market. Formed through the merger of Thermo Electron and Fisher Scientific, the American biotechnology company is headquartered in Waltham, Massachusetts. In proteomics, Thermo Fisher is indispensable, providing a vast portfolio of instruments, reagents, consumables, and services essential for large-scale protein analysis. The company is particularly renowned for its cutting-edge mass spectrometry technology, including the high-resolution Orbitrap family (such as the Orbitrap Exploris and Orbitrap Fusion series), which is a core platform for protein identification, quantification, and post-translational modification analysis. Beyond instruments, Thermo Fisher offers advanced chromatography systems and specialized reagents that streamline workflows for researchers in academic institutions, biopharmaceutical companies, and clinical laboratories. Through its commitment to integrating robust instrumentation with innovative consumables, Thermo Fisher supports the full spectrum of proteomics applications, from basic research and biomarker discovery to clinical diagnostics and the development of personalized medicine, cementing its role as a key global provider in the field.
Latest Market Research Report on Proteomics Download PDF Brochure Now
Danaher Corporation
Danaher Corporation is a diversified global science and technology conglomerate that is a major player in the proteomics market, primarily through its life sciences and diagnostics operating companies. Founded in 1984 and headquartered in Washington, D.C., Danaher has a strong growth strategy driven by strategic acquisitions, including expansions into proteomics-relevant sectors. Danaher’s diverse portfolio includes integrated, automated solutions that leverage technologies such as liquid chromatography (LC) systems and mass spectrometry accessories essential for complex proteomic workflows. The corporation’s efforts focus on delivering reliable and reproducible results in critical areas like genomics and molecular diagnostics, where protein analysis is a functional endpoint of biological pathways. By offering a broad range of microfluidics-based components, advanced diagnostic testing systems, and sophisticated lab analytics tools, Danaher provides the necessary technological infrastructure for next-generation precision medicine and high-quality sample preparation. Its sustained investment in R&D and strategic acquisitions ensures it remains a vital enabler of proteomics research and clinical adoption globally.
Agilent Technologies
Agilent Technologies, Inc. is a global leader in analytical instrumentation and laboratory systems, with a core strategy focused on delivering integrated proteomics workflows. Headquartered in Santa Clara, California, Agilent provides innovative instruments, software, services, and consumables designed to enhance precision and throughput in protein research. The company’s microfluidic solutions and robust mass spectrometry instruments, combined with bioinformatics platforms, enable accurate protein identification, quantification, and biomarker development. Specifically, Agilent provides specialized microfluidic chips, such as those used in its Bioanalyzer Protein kits, and high-performance liquid chromatography (HPLC) systems that are critical for sample separation before mass spectrometry analysis. Agilent’s technologies are widely used in high-growth fields like single-cell analysis and genomics, where precise control over minute samples is necessary. By continually developing reliable, high-performance proteomic tools, Agilent helps researchers and clinicians investigate complex protein activities, advance disease diagnostics, and drive precision medicine across academic institutions, clinical laboratories, and industrial settings.
Bruker Corporation
Bruker Corporation is a leading global provider of high-performance scientific instruments and analytical solutions, with a significant specialization in the proteomics market. Founded in 1960 and headquartered in Billerica, Massachusetts, Bruker drives innovation across materials research, life sciences, and diagnostics. In proteomics, Bruker is renowned for its advanced mass spectrometry platforms, notably the timsTOF Pro and timsTOF Pro 2 series. These systems leverage ion mobility separation (diaPASEF) to offer unparalleled reproducibility, superior sensitivity, and high detection depth for protein quantification. These instruments are instrumental in overcoming traditional proteomic challenges by minimizing missing values and batch effects, which is crucial for large cohort and clinical studies. By providing cutting-edge platforms that can identify and quantify significantly more proteins, including low-abundance biomarkers, from smaller sample inputs, Bruker supports comprehensive proteome coverage. The company’s technology is a foundational tool for advanced proteomics, phosphoproteomics, and biomarker discovery in research institutions and pharmaceutical development, firmly establishing Bruker as a key market leader.
Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. is a leading global provider of products and solutions for the life sciences research and clinical diagnostics markets, maintaining a prominent presence in the proteomics field. Founded in 1952, the company, headquartered in Hercules, California, offers a comprehensive suite of tools for protein analysis. Its proteomics portfolio includes established workhorse technologies such as protein electrophoresis systems (like SDS-PAGE), western blotting platforms, and sophisticated imaging solutions, which are foundational techniques in almost every proteomics lab. The company also contributes to the field through its capabilities in multiplex assays and single-cell genomics. By providing reliable and high-quality reagents, consumables, and instrumentation designed to streamline protein separation, detection, and analysis, Bio-Rad helps scientists and clinicians globally to better understand protein functions, identify disease biomarkers, and accelerate therapy development. The company’s continued dedication to robust, high-quality laboratory products solidifies its importance in the proteomics infrastructure, supporting high-quality results and consistent performance across academic and industrial research.
Illumina
Illumina, Inc. is globally recognized as the leader in DNA sequencing and array-based technologies, but its strategic role in proteomics is rapidly growing, particularly in linking genomics and proteomics research. Headquartered in San Diego, California, Illumina’s technologies, especially its next-generation sequencing (NGS) platforms, are critical for the readout and analysis of certain high-plex proteomics assays. Its core sequencing platforms fundamentally rely on microfluidic chips to manage reagent flow, demonstrating a deep expertise in handling minute volumes—a key requirement for modern high-throughput biology. More recently, Illumina significantly expanded its direct footprint in proteomics through the acquisition of SomaLogic. This integration brings a pioneering platform capable of profiling thousands of proteins simultaneously to the company’s portfolio. This strategic move aims to combine large-scale genomic and proteomic data to advance biomarker discovery, precision medicine, and enhanced disease diagnostics. By leveraging its global reach and technological power, Illumina is transforming the field by providing a systems-level understanding of biological processes essential for tailored healthcare solutions and fundamental research.
Merck KGaA
Merck KGaA, the German multinational science and technology company, is a leading supplier of comprehensive solutions for proteomics applications within its Life Science business. As a provider of laboratory materials and technologies, Merck offers a vast array of products and services that cater to the needs of pharmaceutical, biopharmaceutical, academic, and industrial researchers. Its offerings cover the entire proteomics workflow, including kits and reagents for protein expression, purification, and characterization. The company’s portfolio encompasses products for various proteomic techniques, such as chromatography, electrophoresis, protein microarrays, and mass spectrometry accessories. Merck’s commitment to high-quality reagents and specialized tools helps researchers overcome complex challenges in protein analysis, enabling them to achieve reliable and consistent results for drug discovery and clinical diagnostics. By consistently expanding its product range and supporting technological advancements in the lab, Merck KGaA maintains a vital position as an essential supplier in the proteomics infrastructure ecosystem globally.
Olink
Olink is a specialized Swedish company at the forefront of the proteomics revolution, singularly focused on providing advanced solutions for high-quality protein biomarker discovery. Olink’s core innovation is the Proximity Extension Assay (PEA) technology, which utilizes oligonucleotide-labeled antibody pairs and a PCR-like readout to achieve high sensitivity and multiplexed protein quantification. This unique platform allows researchers to accurately measure thousands of proteins (such as over 5,300 proteins on their Explore HT platform) from minimal sample volumes, typically just a few microliters of plasma or serum. Olink offers various advanced solutions, including Olink Target panels and Olink Explore, which are widely used in academic and clinical research, as well as pharmaceutical development. The company generates revenue through both the sale of its assay kits for customers to run in their own labs and through fee-for-service analysis. By enabling high-throughput, high-quality, and scalable protein analysis, Olink is a key driver in unlocking the complexities of the human proteome and accelerating biomarker validation and personalized medicine.
Waters Corporation
Waters Corporation is a global leader in analytical technologies, specializing in separation science and mass spectrometry, which are foundational pillars of quantitative proteomics. Headquartered in Milford, Massachusetts, Waters provides innovative laboratory instruments and software used by researchers in the life sciences, clinical, and applied chemical markets. Their primary contribution to proteomics lies in high-performance liquid chromatography (HPLC) and ultra-performance liquid chromatography (UPLC) systems that offer superior resolution and speed for separating complex protein mixtures prior to mass spectrometry analysis. Waters’ mass spectrometers are known for their precision and reliability, essential for accurate protein identification and quantification. The company has further expanded its proteomics portfolio through strategic moves, such as the acquisition of Wyatt Technology, enhancing its offerings in separation and detection solutions. By providing end-to-end solutions that ensure the quality and consistency of proteomic data, Waters remains a critical enabler of scientific research and development, supporting drug discovery and regulatory compliance globally.
SomaLogic
SomaLogic is a groundbreaking biotechnology company that is transforming healthcare through its industry-leading proteomics platform. Founded in 2000 and headquartered in Boulder, Colorado, SomaLogic specializes in developing advanced technologies for measuring and analyzing thousands of proteins simultaneously to provide deep insights into health, disease, and drug development. Their pioneering platform offers unparalleled coverage of the human proteome, reportedly measuring over 7,000 proteins in a single, small sample. This ultra-high multiplexing capability is powered by their proprietary SomaScan technology, which uses a unique protein-capture reagent to deliver comprehensive proteomic profiling. SomaLogic’s focus is on personalized medicine, with its technology being used to identify and validate novel protein biomarkers for early disease diagnosis, risk prediction, and monitoring therapeutic efficacy. As a key innovator in the market, SomaLogic’s mission is to revolutionize life sciences and healthcare by making complex proteomic data more accessible and actionable for researchers and clinicians globally, including through its integration with Illumina.
Latest Market Research Report on Proteomics Download PDF Brochure Now